EP3310356A4 - Compositions for the improvement of distance vision and the treatment of refractive errors of the eye - Google Patents
Compositions for the improvement of distance vision and the treatment of refractive errors of the eye Download PDFInfo
- Publication number
- EP3310356A4 EP3310356A4 EP16812174.7A EP16812174A EP3310356A4 EP 3310356 A4 EP3310356 A4 EP 3310356A4 EP 16812174 A EP16812174 A EP 16812174A EP 3310356 A4 EP3310356 A4 EP 3310356A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- eye
- compositions
- improvement
- treatment
- distance vision
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title 1
- 208000014733 refractive error Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/742,903 US9320709B2 (en) | 2013-08-28 | 2015-06-18 | Storage stable compositions and methods for the treatment of refractive errors of the eye |
| US14/742,921 US9314427B2 (en) | 2013-08-28 | 2015-06-18 | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
| PCT/US2016/036692 WO2016205069A1 (en) | 2015-06-18 | 2016-06-09 | Compositions for the improvement of distance vision and the treatment of refractive errors of the eye |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3310356A1 EP3310356A1 (en) | 2018-04-25 |
| EP3310356A4 true EP3310356A4 (en) | 2018-12-05 |
Family
ID=57545598
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP16812173.9A Pending EP3310336A4 (en) | 2015-06-18 | 2016-06-09 | Storage stable compositions and methods for the treatment of refractive errors of the eye |
| EP16812174.7A Pending EP3310356A4 (en) | 2015-06-18 | 2016-06-09 | Compositions for the improvement of distance vision and the treatment of refractive errors of the eye |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP16812173.9A Pending EP3310336A4 (en) | 2015-06-18 | 2016-06-09 | Storage stable compositions and methods for the treatment of refractive errors of the eye |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP3310336A4 (en) |
| JP (3) | JP6835747B2 (en) |
| KR (4) | KR20180014825A (en) |
| CN (3) | CN116808032A (en) |
| AU (2) | AU2016280615B2 (en) |
| CA (2) | CA2987787C (en) |
| HK (1) | HK1254338A1 (en) |
| MX (2) | MX2017016517A (en) |
| WO (2) | WO2016205069A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180014825A (en) * | 2015-06-18 | 2018-02-09 | 프레스바이오피아 세라피스, 엘엘씨 | Compositions and methods for the treatment of abnormal refraction of eyes and improvement of distance vision |
| CN110505876A (en) * | 2017-03-23 | 2019-11-26 | 新加坡保健服务集团 | The medicament for pre- myopia prevention, treatment myopia and/or prevention mypia progression comprising tiotropium as active constituent |
| CA3063228C (en) | 2017-05-11 | 2022-06-28 | Nevakar Inc. | Atropine pharmaceutical compositions |
| EP4228636A1 (en) * | 2020-10-13 | 2023-08-23 | Lenz Therapeutics, Inc. | Compositions and methods for storage stable ophthalmic drugs |
| AU2021369566A1 (en) * | 2020-11-02 | 2023-06-22 | Visus Therapeutics, Inc. | Degradant compound in a medicament |
| EP4308080A1 (en) * | 2021-03-16 | 2024-01-24 | Vyluma Inc. | Multi-dose container for ophthalmic compositions |
| KR20220154509A (en) | 2021-05-13 | 2022-11-22 | 전연우 | A medicine bottle that tells you when to take it and allows you to take it out comfortably |
| TW202333700A (en) * | 2021-12-16 | 2023-09-01 | 美商倫茨治療公司 | Compositions and methods for the treatment of eye conditions |
| KR20230126461A (en) * | 2022-02-23 | 2023-08-30 | 주식회사 스카이테라퓨틱스 | A structure of polymer hyaluronic acid, manufacturing method thereof and cosmetic composition comprising the same |
| KR20230126522A (en) * | 2022-02-23 | 2023-08-30 | 주식회사 스카이테라퓨틱스 | A structure of polymer hyaluronic acid, manufacturing method thereof and eye drop composition comprising the same |
| WO2023172240A1 (en) * | 2022-03-07 | 2023-09-14 | Harrow Ip, Llc | Extended-release pharmaceutical compositions for treating eye conditions |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015031186A1 (en) * | 2013-08-28 | 2015-03-05 | Presbyopia Theraplies, Llc | Compositions and methods for the treatment of presbyopia |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474751A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
| US6291466B1 (en) | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
| BR0015416A (en) * | 1999-11-09 | 2002-07-16 | Alcon Inc | Compositions containing tetraenoic hydroxyieic acid derivatives and methods of use in the treatment of dry eye disorders |
| ITMI20010708A1 (en) * | 2001-04-03 | 2002-10-03 | Alessandro Randazzo | PHARMACOLOGICAL TREATMENT OF NIGHT BLINDS AND GHOST IMAGES WITH DILUTED PARASYMPATHOMYMETICS ACECLIDINE / PILOCARPINE AFTER INTER |
| JP5583310B2 (en) * | 2002-12-20 | 2014-09-03 | チャクシュ・リサーチ・インコーポレーテッド | Ophthalmic formulation for prevention and treatment of ocular symptoms |
| US20060177430A1 (en) * | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
| US20050196370A1 (en) * | 2003-03-18 | 2005-09-08 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
| DE602006008643D1 (en) | 2006-12-18 | 2009-10-01 | Jorge Luis Benozzi | Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia |
| WO2009072007A2 (en) * | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| CA2849366C (en) | 2011-09-20 | 2019-09-10 | Juan Carlos Abad | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
| MY171920A (en) * | 2011-10-12 | 2019-11-07 | Ascendis Pharma Ophthalmology Div A/S | Prevention and treatment of ocular conditions |
| US20140378401A1 (en) * | 2013-06-21 | 2014-12-25 | Gnt, Llc | Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations |
| US9573840B2 (en) * | 2013-08-27 | 2017-02-21 | Corning Incorporated | Antimony-free glass, antimony-free frit and a glass package that is hermetically sealed with the frit |
| KR20180014825A (en) | 2015-06-18 | 2018-02-09 | 프레스바이오피아 세라피스, 엘엘씨 | Compositions and methods for the treatment of abnormal refraction of eyes and improvement of distance vision |
-
2016
- 2016-06-09 KR KR1020187000612A patent/KR20180014825A/en not_active IP Right Cessation
- 2016-06-09 AU AU2016280615A patent/AU2016280615B2/en active Active
- 2016-06-09 KR KR1020187000609A patent/KR102598047B1/en active IP Right Grant
- 2016-06-09 MX MX2017016517A patent/MX2017016517A/en active IP Right Grant
- 2016-06-09 KR KR1020237018669A patent/KR20230085217A/en active IP Right Grant
- 2016-06-09 WO PCT/US2016/036692 patent/WO2016205069A1/en active Application Filing
- 2016-06-09 CA CA2987787A patent/CA2987787C/en active Active
- 2016-06-09 CN CN202310360068.XA patent/CN116808032A/en active Pending
- 2016-06-09 CN CN201680035682.7A patent/CN107847492B/en active Active
- 2016-06-09 JP JP2017565201A patent/JP6835747B2/en active Active
- 2016-06-09 EP EP16812173.9A patent/EP3310336A4/en active Pending
- 2016-06-09 WO PCT/US2016/036687 patent/WO2016205068A1/en active Application Filing
- 2016-06-09 KR KR1020237037557A patent/KR20230156161A/en active Search and Examination
- 2016-06-09 EP EP16812174.7A patent/EP3310356A4/en active Pending
- 2016-06-09 MX MX2017016518A patent/MX2017016518A/en active IP Right Grant
- 2016-06-09 AU AU2016280616A patent/AU2016280616B2/en active Active
- 2016-06-09 CN CN201680035276.0A patent/CN107920984A/en active Pending
- 2016-06-09 JP JP2017565154A patent/JP6838712B2/en active Active
- 2016-06-09 CA CA2987783A patent/CA2987783A1/en active Pending
-
2018
- 2018-10-18 HK HK18113414.1A patent/HK1254338A1/en unknown
-
2020
- 2020-10-20 JP JP2020175809A patent/JP7026189B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015031186A1 (en) * | 2013-08-28 | 2015-03-05 | Presbyopia Theraplies, Llc | Compositions and methods for the treatment of presbyopia |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3310356A1 (en) | 2018-04-25 |
| KR20230085217A (en) | 2023-06-13 |
| CN107847492B (en) | 2021-05-25 |
| CN107920984A (en) | 2018-04-17 |
| JP6835747B2 (en) | 2021-02-24 |
| MX2017016518A (en) | 2018-05-28 |
| CA2987783A1 (en) | 2016-12-22 |
| HK1254338A1 (en) | 2019-07-19 |
| JP2021035954A (en) | 2021-03-04 |
| AU2016280616B2 (en) | 2020-10-22 |
| CA2987787C (en) | 2023-06-27 |
| KR20180014825A (en) | 2018-02-09 |
| MX2017016517A (en) | 2018-05-28 |
| BR112017025722A2 (en) | 2018-08-07 |
| EP3310336A1 (en) | 2018-04-25 |
| KR20180014824A (en) | 2018-02-09 |
| KR20230156161A (en) | 2023-11-13 |
| JP7026189B2 (en) | 2022-02-25 |
| AU2016280615A1 (en) | 2017-12-14 |
| CN107847492A (en) | 2018-03-27 |
| EP3310336A4 (en) | 2018-12-05 |
| CA2987787A1 (en) | 2016-12-22 |
| JP2018517738A (en) | 2018-07-05 |
| JP2018517740A (en) | 2018-07-05 |
| WO2016205069A1 (en) | 2016-12-22 |
| AU2016280615B2 (en) | 2020-10-01 |
| AU2016280616A1 (en) | 2017-12-14 |
| KR102598047B1 (en) | 2023-11-06 |
| BR112017025726A2 (en) | 2018-08-14 |
| CN116808032A (en) | 2023-09-29 |
| WO2016205068A1 (en) | 2016-12-22 |
| JP6838712B2 (en) | 2021-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3310356A4 (en) | Compositions for the improvement of distance vision and the treatment of refractive errors of the eye | |
| EP3347469A4 (en) | Methods and compositions for the treatment of glaucoma | |
| EP3177732A4 (en) | Compositions and methods for the treatment of ophthalmic diseases and conditions | |
| EP3390634A4 (en) | Compositions and methods for treatment of eye diseases | |
| EP3160471A4 (en) | Ophthalmic composition | |
| GB201913962D0 (en) | Ophthalmic drug compositions | |
| EP3291765A4 (en) | Methods of delivering an agent to the eye | |
| EP3096617A4 (en) | Compositions and methods for treating ocular diseases | |
| EP3500255A4 (en) | Ophthalmic pharmaceutical compositions and uses relating thereto | |
| EP3472317A4 (en) | Compositions and methods for reducing ocular neovascularization | |
| EP3265096A4 (en) | Ophthalmic compositions and methods of use therefor | |
| EP3164058A4 (en) | Systems and methods for alignment of the eye for ocular imaging | |
| EP3452075A4 (en) | Ophthalmic pharmaceutical composition | |
| EP3352749A4 (en) | Compounds and compositions for the treatment of ocular disorders | |
| EP3397995A4 (en) | Ophthalmic lens | |
| EP3672587A4 (en) | Pharmaceutical compositions for the treatment of ophthalmic conditions | |
| EP3481411A4 (en) | Treatment for glaucoma and other eye diseases | |
| EP3185825A4 (en) | Surgical eye shield | |
| EP3672598A4 (en) | Ocular pharmaceutical compositions | |
| GB2541840B (en) | Ophthalmic composition for the treatment of ocular infection | |
| IL282504A (en) | Ocular formulations for drug-delivery and protection of the anterior segment of the eye | |
| EP3216451A4 (en) | Ophthalmic aqueous composition | |
| EP3452015A4 (en) | Compositions and methods for treatment of inflammation or infection of the eye | |
| PL3072503T3 (en) | Ophthalmic composition for the corneal protection | |
| EP3265103A4 (en) | Compositions and methods for treating ocular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20180104 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20181029 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/00 20060101ALI20181023BHEP Ipc: A61P 27/10 20060101ALI20181023BHEP Ipc: A61K 31/439 20060101AFI20181023BHEP Ipc: A61K 9/08 20060101ALI20181023BHEP Ipc: A61K 47/26 20060101ALI20181023BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20200512 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PRESBYOPIA THERAPIES, INC. |
|
| RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: LENZ THERAPEUTICS, INC. |